Notoginsenoside R2

Synonyms: 三七皂苷R2; 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2
Notoginsenoside R2(20(S)-Notoginsenoside R2;Ginsenoside Ng-R2)是一种具有口服活性的三七皂苷,它通过 MEK1/2-ERK1/2 通路激活 P90RSK 与 Nrf2,抑制 6-OHDA 诱导的神经细胞凋亡 (apoptosis) 损伤,并通过降低 miR-27a、上调 SOX8/β-catenin 抑制 Aβ25-35 诱导的神经元凋亡与炎症反应,同时通过抑制 c-Src 减轻糖尿病肾病脂质蓄积与线粒体功能障碍,还通过抑制 JAK/STAT3 诱导肝星状细胞衰老及抑制炎症微环境减轻肝纤维化。
产品编号: MS-L38693 纯度: 99.80% CAS No.: 80418-25-3 分子式: C41H70O13 分子量: 770.99
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Notoginsenoside R2(20(S)-Notoginsenoside R2;Ginsenoside Ng-R2)是一种具有口服活性的三七皂苷,它通过 MEK1/2-ERK1/2 通路激活 P90RSK 与 Nrf2,抑制 6-OHDA 诱导的神经细胞凋亡 (apoptosis) 损伤,并通过降低 miR-27a、上调 SOX8/β-catenin 抑制 Aβ25-35 诱导的神经元凋亡与炎症反应,同时通过抑制 c-Src 减轻糖尿病肾病脂质蓄积与线粒体功能障碍,还通过抑制 JAK/STAT3 诱导肝星状细胞衰老及抑制炎症微环境减轻肝纤维化。

生物实验数据

生物活性 Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active Panax notoginseng saponin that inhibits 6-OHDA-induced neuronal apoptosis injury by activating P90RSK and Nrf2 via the MEK1/2-ERK1/2 pathway, suppresses Aβ25-35-induced neuronal apoptosis and inflammatory responses by downregulating miR-27a and upregulating SOX8/β-catenin, alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src, and attenuates liver fibrosis by inhibiting JAK/STAT3 to induce hepatic stellate cell senescence and suppress the inflammatory microenvironment.
体外研究
(In Vitro)

Notoginsenoside R2 (20 μM; 24 h) 可保护 SH-SY5Y 细胞免受 6-OHDA (MS-Q40892) 诱导的细胞死亡,TUNEL 阳性细胞计数减少及总体凋亡率降低。
Notoginsenoside R2 (20 μM; 24 h) 可降低 6-OHDA 诱导的 SH-SY5Y 细胞、PC12 细胞及原代皮质神经元的 LDH 释放。
Notoginsenoside R2 (20 μM; 24 h) 可抑制 6-OHDA 诱导的 SH-SY5Y 细胞氧化应激,表现为细胞内 ROS 生成和 MDA 水平降低,逆转细胞线粒体膜去极化。
Notoginsenoside R2 (20 μM) 提高 SH-SY5Y 细胞中 HO-1、GSH-PX 和 GR 的活性,且预孵育 24 h 可逆转 6-OHDA 诱导的上述酶活性降低及核内 Nrf2 聚集水平下降。
Notoginsenoside R2 (20 μM; 4-24 h) 可激活 SH-SY5Y 细胞中的 MEK1/2-ERK1/2 信号通路,进而诱导下游 P90RSK 和 Nrf2 的激活,后者可介导抑制 6-OHDA 诱导的凋亡蛋白表达;而上述通路的激活依赖于 MEK1/2-ERK1/2 信号传导,但不依赖于 JNK、p38 或 PI3K/Akt 信号传导。
Notoginsenoside R2 (10-30 μM) 可剂量依赖性地减轻 Aβ25-35 (MS-O24173) 诱导的原代大鼠皮质神经元凋亡,降低活化型 caspase-3、miR-27a 表达水平,并下调 COX-2 的表达,上调 SOX8 的 mRNA 和蛋白表达,上调总 β-catenin 蛋白及核内 β-catenin 蛋白的表达。
Notoginsenoside R2 (10-40 μM; 24 h) 可通过抑制 c-Src 活化,减轻高血糖与棕榈酸 (HGPA) 刺激的 HK-2 细胞中的脂质蓄积、氧化应激、线粒体功能障碍及细胞凋亡。
Notoginsenoside R2 (10-100 μM; 24 h) 抑制 HSC-T6 细胞增殖。
Notoginsenoside R2 (20-30 μM; 24 h) 下调 HSC-T6 细胞中 α-SMA 和 COL-I 的 mRNA 和蛋白表达。
Notoginsenoside R2 (20 μM; 24 h) 可在 HSC-T6 细胞中下调纤维化标志物 (α-SMA、COL-I、Desmin、TIMP-1),并上调衰老标志物 (p16、p21、p53)。
Notoginsenoside R2 (20 μM; 24 h) 抑制 HSC-T6 细胞中的 JAK/STAT3 信号通路。
Notoginsenoside R2 (20 μM; 24 h) 抑制 HSC-T6 细胞中促炎细胞因子的 mRNA 表达。
Notoginsenoside R2 (20 μM; 24 h) 上调 HSC-T6 细胞中 SASP 组分的 mRNA 表达。
Notoginsenoside R2 (20 μM; 24 h) 可降低 HSC-T6 细胞内的 ROS 水平。
Notoginsenoside R2 (20 μM; 24 h) 诱导 HSC-T6 细胞发生衰老。

Apoptosis Analysis

Cell Line: SH-SY5Y human neuroblastoma cells
Concentration: 20 μM
Incubation Time: 24 h (pre-incubation)
Result: Significantly reduced the number of TUNEL-positive cells and the overall apoptosis rate induced by 6-OHDA.
Had no effect on apoptosis rate or TUNEL-positive cell count when treated alone.

Western Blot Analysis

Cell Line: SH-SY5Y human neuroblastoma cells
Concentration: 20 μM
Incubation Time: 4 h, 8 h, 16 h, 20 h, 24 h
Result: Increased phosphorylation of P90RSK, BAD, MEK1/2, and ERK1/2, and enhanced nuclear Nrf2 accumulation in a time-dependent manner when treated alone, with MEK1/2 phosphorylation peaking at 16 h and ERK1/2 phosphorylation peaking at 20 h.
Blocked 6-OHDA-induced increases in cytochrome c release, cleaved caspase-9, and cleaved caspase-3, and reversed 6-OHDA-induced reductions in p-BAD levels when pre-incubated for 24 h.
Induced P90RSK phosphorylation and nuclear Nrf2 accumulation were prevented by pre-incubation with MEK1/2 inhibitor PD98059, while JNK, p38, or PI3K/Akt inhibitors had no effect.
Induced phosphorylation of ERK1/2, P90RSK, and BAD, as well as nuclear Nrf2 accumulation and increases in HO-1, GSH-PX, and GR activities were blocked by MEK1/2 or ERK1/2 siRNA transfection.
Induced increases in HO-1, GSH-PX, and GR activities were blocked by Nrf2 siRNA transfection.

Cell Viability Assay

Cell Line: HSC-T6 hepatic stellate cells
Concentration: 10, 20, 40, 80, 100 μM
Incubation Time: 24 h
Result: Suppressed HSC-T6 cell proliferation in a dose-dependent manner at concentrations of 40-100 μM.
Caused statistically significant reductions in cell viability at 80 μM and 100 μM relative to the normal control.

Real Time qPCR

Cell Line: HSC-T6 cells
Concentration: 20, 30 μM
Incubation Time: 24 h
Result: Caused a marked reduction in mRNA expression of α-SMA relative to the normal control.
Caused a marked reduction in mRNA expression of COL-I relative to the normal control.

Immunofluorescence

Cell Line: HSC-T6 cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Significantly decreased the area of α-SMA staining in HSC-T6 cells relative to the normal control.
Significantly decreased the area of COL-I staining in HSC-T6 cells relative to the normal control.

Western Blot Analysis

Cell Line: HSC-T6 cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Significantly reduced protein expression of α-SMA relative to the normal control.
Significantly reduced protein expression of COL-I) relative to the normal control.
Significantly reduced protein expression of Desmin relative to the normal control.
Significantly reduced protein expression of TIMP-1 relative to the normal control.
Significantly increased protein expression of p16 relative to the normal control.
Significantly increased protein expression of p21 relative to the normal control.
Significantly increased protein expression of p53 relative to the normal control.\nSignificantly reduced the phosphorylation of JAK relative to the normal control.
Significantly reduced the phosphorylation of STAT3 relative to the normal control.
Left total JAK and STAT3 protein levels unchanged.

Real Time qPCR

Cell Line: HSC-T6 cells
Concentration: 20 μM
Incubation Time: 24 h
Result: Significantly reduced mRNA expression of pro-inflammatory mediators including IL-6, IL-1β, CCL2, IL-8, and TNF-α relative to the normal control.\nSignificantly upregulated mRNA expression of SASP components including p16, p21, p53, and MMP10 relative to the normal control.
体内研究
(In Vivo)

Notoginsenoside R2 (250 mg/kg,腹腔注射,每日一次,连续 20 周) 可改善自发性阿尔茨海默病模型 SAMP8 小鼠的认知功能,减少海马神经元凋亡,并调控凋亡及炎症相关蛋白的表达。
Notoginsenoside R2 (250 mg/kg;腹腔注射;每日一次;连续 20 周) 可改善 Aβ25-35 诱导的阿尔茨海默病大鼠的认知功能,减少海马神经元凋亡,并调控凋亡及炎症相关蛋白的表达。
Notoginsenoside R2 (20-40 mg/kg,每日口服,持续 8 周) 可改善糖尿病肾病模型 db/db 小鼠的肾功能障碍、组织病理学损伤、脂质蓄积、氧化应激、线粒体功能障碍及细胞凋亡,其作用部分通过抑制 c-Src 的激活实现。
Notoginsenoside R2 (6.25-25 μM; 于 TAA 预处理 72 小时后给药) 可通过 STAT3 依赖性途径减轻氧化应激、炎症反应并诱导肝星状细胞衰老,从而呈剂量依赖性地缓解斑马鱼中由 TAA (MS-A54832) 诱导的肝纤维化。

Animal Model: SAMP8 (male, 3-month-old, 20-30 g, spontaneous Alzheimer's disease model); SAMR1 (male, normal aging control)
Dosage: 250 mg/kg
Administration: i.p.; daily; 20 consecutive weeks
Result: Reduced learning reaction time to 25.23 s.
Reduced learning error time to 4.52.
Increased memory reaction time to 180 s.
Reduced memory error time to 5.41.
Alleviated hippocampal neuronal disorganization and loss of pyramidal cells.
Reduced TUNEL-positive apoptotic cells compared to the AD group.
Decreased cleaved caspase-3 and COX-2 protein expression compared to the AD group.
Increased SOX8 and β-catenin protein expression compared to the AD group.
Animal Model: Sprague-Dawley (male, 18-20 months-old, 200-220 g, Aβ25-35-induced Alzheimer's disease model via bilateral hippocampal injection); Sprague-Dawley (male, 3-6 months-old, control)
Dosage: 250 mg/kg
Administration: i.p.; daily; 20 consecutive weeks
Result: Reduced learning reaction time to 25.23 s.
Reduced learning error time to 3.98.
Increased memory reaction time to 182.32 s.
Reduced memory error time to 6.23.
Restored hippocampal neuronal structure compared to the Aβ25-35-treated group.
Reduced TUNEL-positive apoptotic cells compared to the Aβ25-35-treated group.
Decreased cleaved caspase-3 and COX-2 protein expression compared to the Aβ25-35-treated group.
Increased SOX8 and β-catenin protein expression compared to the Aβ25-35-treated group.
Animal Model: C57BKS/Lepr db/db (male, 7-8 weeks old, spontaneous diabetic nephropathy with elevated urine albumin-to-creatinine ratios)
Dosage: 20 mg/kg/day; 40 mg/kg/day
Administration: p.o.; daily; 8 weeks
Result: Reduced urine albumin-to-creatinine ratios (ACR) levels compared to untreated db/db mice, with 40 mg/kg dose causing greater reduction than positive control Losartan.
Significantly lowered serum creatinine (Scr) and blood urea nitrogen (BUN) levels relative to untreated db/db mice at 40 mg/kg dose; significantly reduced Scr levels at 20 mg/kg dose.
Significantly reduced serum total cholesterol (TC) levels compared to untreated db/db mice at 20 mg/kg dose; reduced TC levels to a greater, statistically significant extent at 40 mg/kg dose.
Left serum triglyceride (TG) levels unchanged with either dose.
Unaffected liver function markers (ALT, AST), indicating no liver toxicity.
Ameliorated renal histopathological abnormalities including mesangial expansion, glycogen deposition, collagen fiber deposition, and podocyte foot process effacement, and significantly reduced renal expression of fibrosis-related proteins (fibronectin, vimentin, α-SMA) at both doses.
Significantly reduced intrarenal lipid accumulation (measured by Oil Red O staining and renal triglyceride content), and suppressed renal expression of phosphorylated c-Src (Tyr416), phosphorylated JNK, phosphorylated STAT1, and CD36 at both doses.
Reduced renal malondialdehyde (MDA) levels, increased superoxide dismutase (SOD), glutathione (GSH), glutathione reductase (GR), catalase (CAT), and ATP levels relative to untreated db/db mice at both doses.
Downregulated renal expression of mitochondrial fission proteins Drp1 and Fis1, and upregulated the mitochondrial fusion protein Mfn2 at both doses.
Reduced renal TUNEL-positive apoptotic cells, lowered expression of pro-apoptotic proteins (Bax, cleaved-caspase-3), and increased expression of the anti-apoptotic protein Bcl-2 at both doses.
Animal Model: wild-type AB strain; transgenic Tg(lfabp10α:eGFP) strain (2-day post-fertilization larvae)
Dosage: 6.25 μM; 12.5 μM; 25 μM (general); 25 μM (STAT3-knockdown zebrafish)
Administration: administered following 72-hour TAA preconditioning
Result: Caused no notable morphological abnormalities, developmental delays, or hatching rate differences compared to untreated controls at 6.25 μM, 12.5 μM, and 25 μM.
Significantly mitigated TAA-induced hepatic damage (reduced intercellular gaps, hepatocellular enlargement, and vacuolation) as observed via H&E staining, and dose-dependently reduced mRNA levels of fibrotic markers α-SMA and COL-I at 6.25 μM, 12.5 μM, and 25 μM.
Significantly reduced hepatic reactive oxygen species (ROS) levels, reduced mRNA expression of pro-inflammatory cytokines (IL-6, IL-1β, CCL2, IL-8, TNF-α), reduced STAT3 protein levels and JAK/STAT3 pathway gene expression, and significantly upregulated protein and mRNA levels of senescence biomarkers p16 and p21, plus SASP components including p53 at 25 μM.
Lost antifibrotic effects in STAT3-knockdown zebrafish: no longer mitigated hepatic vacuolation/tissue disorganization, failed to reduce α-SMA and COL-I mRNA levels, showed diminished ROS suppression, lost anti-inflammatory activity, and no longer upregulated senescence biomarkers p16 and p21 or SASP components at 25 μM.
性状 固体
颜色 White to off-white

化学信息

分子量 770.99
分子式 C41H70O13
CAS No. 80418-25-3
别名 三七皂苷R2; 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.59 mM), Sonication is recommended.
10% DMSO+90% Saline: 10 mg/mL (12.97 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (129.70 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.2970 mL6.4852 mL12.9703 mL32.4258 mL
5 mM0.2594 mL1.2970 mL2.5941 mL6.4852 mL
10 mM0.1297 mL0.6485 mL1.2970 mL3.2426 mL
15 mM0.0865 mL0.4323 mL0.8647 mL2.1617 mL
20 mM0.0649 mL0.3243 mL0.6485 mL1.6213 mL
25 mM0.0519 mL0.2594 mL0.5188 mL1.2970 mL
30 mM0.0432 mL0.2162 mL0.4323 mL1.0809 mL
40 mM0.0324 mL0.1621 mL0.3243 mL0.8106 mL
50 mM0.0259 mL0.1297 mL0.2594 mL0.6485 mL
60 mM0.0216 mL0.1081 mL0.2162 mL0.5404 mL
80 mM0.0162 mL0.0811 mL0.1621 mL0.4053 mL
100 mM0.0130 mL0.0649 mL0.1297 mL0.3243 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

三七皂甙 R2 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础